| Code | URI | Type | Description |
| Specializes | | Coding | The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric. |
| Generalizes | | Coding | Inverse of Specializes. Only included as a derived relationship. |
| internalId | http://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-id | code | The internal identifier for the concept in the HL7 Access database repository. |
| notSelectable | http://hl7.org/fhir/concept-properties#notSelectable | boolean | Indicates that the code is abstract - only intended to be used as a selector for other concepts |
| status | http://hl7.org/fhir/concept-properties#status | code | Designation of a concept's state. Normally is not populated unless the state is retired. |
| Lvl | Code | Display | Definition | internalId | Not Selectable | status |
| 1 | _ActSubstanceAdminSubstitutionCode | ActSubstanceAdminSubstitutionCode | **Description:** Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. | 21284 | true | active |
| 2 | E | equivalent | **Description:** Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. | 23107 | | active |
| 3 | EC | equivalent composition | **Description:** \r\n\r\nSubstitution occurred or is permitted with another product that is a:\r\n\r\n * pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester\r\n * pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration\r\n\r\n*Examples:* \r\n\r\n * *Pharmaceutical alternative:* Erythromycin Ethylsuccinate for Erythromycin Stearate\r\n * *Pharmaceutical equivalent:* Lisonpril for Zestril | 23108 | | active |
| 4 | BC | brand composition | **Description:** \r\n\r\nSubstitution occurred or is permitted between equivalent Brands but not Generics\r\n\r\n*Examples:* \r\n\r\n * Zestril for Prinivil\r\n * Coumadin for Jantoven | 23109 | | active |
| 4 | G | generic composition | **Description:** Substitution occurred or is permitted between equivalent Generics but not Brands\r\n\r\n*Examples:* \r\n\r\n * Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) | 16623 | | active |
| 3 | TE | therapeutic alternative | **Description:** Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.\r\n\r\n*Examples:* \r\n\r\n * ranitidine for Tagamet | 16624 | | active |
| 4 | TB | therapeutic brand | **Description:** Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics\r\n\r\n>\r\n\r\n*Examples:* \r\n\r\n * Zantac for Tagamet | 23105 | | active |
| 4 | TG | therapeutic generic | **Description:** Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands\r\n\r\n>\r\n\r\n*Examples:* \r\n\r\n * Ranitidine for cimetidine | 23106 | | active |
| 2 | F | formulary | **Description:** This substitution was performed or is permitted based on formulary guidelines. | 16625 | | active |
| 2 | N | none | No substitution occurred or is permitted. | 16622 | | active |